-
Featured
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
Brain changes associated with Alzheimer’s disease can now be studied in living people. Mass General researchers imaged cognitively normal people who are destined to develop AD due to a rare genetic mutation. Their goal: to discover how soon brain changes are present before symptoms begin and how soon preventive treatments could be initiated.
-
Featured
NEJM Images in Clinical Medicine: Using Ventriculoperitoneal Shunt Placement to Treat Normal-pressure Hydrocephalus
Neurologists at Mass General explore the case of a woman who endured gait disturbance, cognitive impairment and urinary incontinence for 2 years before she was diagnosed with normal-pressure hydrocephalus and successfully treated with surgical shunting.
-
Featured
fMRI and EEG May Find Signals of Consciousness Earlier in Severe Traumatic Brain Injury Patients
The rate of misclassification of unconsciousness can be as high as 40%. A Mass General team studied using fMRI and EEG to better identify patients with unconsciousness in the ICU.
-
Cortical Network Engagement Differs During Different States of Un/consciousness in Humans
Rina Zelmann, PhD, Sydney S. Cash, MD, PhD, and colleagues observed distinct brain responses during unconsciousness compared to the awake state, with the prefrontal cortex particularly affected by general anesthesia. The results have direct therapeutic implications for clinical applications of deep brain stimulation.
-
Perspective: Using Information on Somatic Mutations to Direct Management of Neurological Disorders
Kristopher T. Kahle, MD, PhD, and colleagues explain that somatic variations detected from neurosurgical biopsies or resection of fresh brain tissue are beginning to suggest which existing targeted medications could be used as monotherapies or adjuncts to surgery for non-oncologic neurological diseases.
-
Developing a Gene Therapy for an Extremely Rare Cerebrovascular Disease
Massachusetts General Hospital physician-scientist Patricia Musolino, MD, PhD, was a key investigator in a clinical trial that led to the first FDA-approved gene therapy for a cerebral disease. Her research is focused on studying rare genetic disorders to develop approaches that may lead to gene therapy treatments.
Neurology Contributors
-
Brian L. Edlow, MD
Associate Director, Center for Neurotechnology and Neurorecovery (CNTR), Director, Laboratory for NeuroImaging of Coma and Consciousness (NICC), Director, Critical Care Research Neuroimaging
Recent Article
Detecting 'Covert Consciousness' in the ICU With TMS-EEG
-
Jodi Gilman, PhD
Director of Neuroscience, Center for Addiction Medicine, Massachusetts General Hospital
Recent Article
Pain Catastrophizing Is Associated With Reduced Neural Response to Monetary Reward
-
Keith A. Johnson, MD
Radiologist
Recent Article
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
-
Nagagopal Venna, MD
Director, Neurology Clinic, Director, Neuro-Infectious Diseases Clinic, Director, Academic General Neurology Fellowship Program
Recent Article
NEJM Images in Clinical Medicine: Using Ventriculoperitoneal Shunt Placement to Treat Normal-pressure Hydrocephalus
-
Yakeel T. Quiroz, PhD
Associate Professor, Harvard Medical School, Director, Familial Dementia Neuroimaging Lab, Director, Multicultural Alzheimer's Prevention Program, Massachusetts General Hospital, Paul B. and Sandra M. Edgerley MGH Research Scholar 2020-2025
Recent Article
Higher Levels of Education Buffer Against Autosomal Dominant Alzheimer's Disease
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.